| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
4 companies
James M Daly is Director at ACAD, with reported holdings spanning 4 companies. James M Daly's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.8M at current prices.
Our model assigns James M Daly a below-average insider score of 37/100, based on 6 past trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -29.2%.
James M Daly's largest disclosed position is in MDGL as Director, worth about $1.2M. The MDGL filings lean toward selling, a net 47,959 shares.
James M Daly has 44 Form 4 filings on record from January 2016 to October 2026, across 4 companies: Director at Cytokinetics (CYTK), 2025–2026; Director at Halozyme Therapeutics (HALO), 2016–2026; Director at Madrigal Pharmaceuticals (MDGL), 2019–2026, and 1 more.
The 91 reported transactions were 32 option or other derivative awards, 27 open-market sales, 18 stock awards and 14 option exercises.
Counted by filing, the open-market trades come to no purchases and 8 sales worth about $19.0M.
The largest open-market sale was 32,489 shares of MDGL at an average $252.97 on April 2, 2024, about $8.2M. Twelve months later MDGL was up 37%.
1 of the 4 sales since April 2023 was made under a Rule 10b5-1 trading plan; the other 3 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 10, 2025 | ACAD Acadia Pharmaceuticals Inc | Director | Sell | 30,000 | $22.37 | $670,983.00 | -88.1% | +4.6% | - | |
| Feb 27, 2025 | MDGL Madrigal Pharmaceuticals, Inc. | Director | Sale+OE | 15,470 | $347.45 | $5,375,125.55 | -89.0% | -19.3% | +28.8% | |
| Apr 2, 2024 | MDGL Madrigal Pharmaceuticals, Inc. | Director | Sale+OE10b5-1 | 32,489 | $252.97 | $8,218,630.32 | -96.4% | +14.2% | +36.9% | |
| Aug 14, 2023 | HALO Halozyme Therapeutics, Inc. | Director | Sell | 20,000 | $43.73 | $874,520.00 | -49.4% | -14.5% | +27.7% | |
| Nov 25, 2020 | HALO Halozyme Therapeutics, Inc. | Director | Sell | 10,363 | $40.41 | $418,799.92 | -33.0% | - | - | |
| Aug 13, 2020 | HALO Halozyme Therapeutics, Inc. | Director | Sell | 34,337 | $29.12 | $999,893.44 | -52.3% | - | - | |
| May 11, 2020 | ACAD Acadia Pharmaceuticals Inc | Director | Sale+OE | 26,250 | $51.13 | $1,342,178.25 | - | - | - | |
| Sep 9, 2019 | ACAD Acadia Pharmaceuticals Inc | Director | Sale+OE | 30,000 | $37.80 | $1,133,860.08 | - | - | - |